#USA #New York #Levi Korsinsky #Fractyl Health #GUTS

GUTS Shareholder Alert: Fractyl Health Class Action

Investors holding shares of Fractyl Health, Inc. (NASDAQ: GUTS) should take note of the recent developments regarding a securities class action that has been initiated. The lawsuit targets shareholders who bought securities between January 13, 2025, and January 29, 2026. The deadline to apply as lead plaintiff is approaching on October 20, 2026. This development comes after a notable decline in GUTS stock, which plummeted by approximately 74.86%, translating to a loss of $1.37 per share over two consecutive trading days.

Market Response to Fractyl Health

Wall Street's response to Fractyl Health has been marked by sharp re-evaluations, with Morgan Stanley reducing its price target significantly from $8.00 to $2.00, reflecting a downgrade from Overweight to Equal-weight. Following the release of the six-month REMAIN-1 Midpoint Cohort results, which were anticipated to bolster investor confidence, analysts expressed concerns over the disappointing findings that indicated the treatment's efficacy might not meet initial expectations. Such fluctuations underscore the volatility and risks inherent in investing in biopharmaceutical companies.

Impact of Analyst Downgrades

The analysis pointed out that Revita-treated patients demonstrated a lesser weight loss compared to controls—4.5% versus 7.5%—a difference significantly short of the targeted improvement threshold. This has led to skepticism regarding Revita's clinical prospects, with analysts reducing the probability of success from 50% to 35% for the treatment and reshaping their sales forecasts accordingly.

Legal Implications for Shareholders

The class action lawsuit, spearheaded by Levi & Korsinsky, LLP, accuses Fractyl of making materially false claims about Revita’s clinical efficacy and the reliability of trial data. The plaintiffs argue that these disclosures were misleading, allowing the stock price to be artificially inflated in anticipation of positive clinical results, ultimately leading to significant losses when the actual data was revealed.

Investors whose losses correlate with the misrepresented data may seek recovery. The firm encourages eligible parties to collect brokerage records validating purchase dates, share quantities, and prices to facilitate potential claims.

Frequently Asked Questions

Q: What caused GUTS stock to drop significantly?
A: Following the disclosure of the disappointing clinical trial results, shares plummeted $1.245 (68.03%) on January 29, 2026, and an additional $0.125 (21.37%) the following day.

Q: What misstatements are alleged in the lawsuit?
A: The complaint asserts that Fractyl misrepresented Revita's efficacy and failed to disclose operational issues at a study site that compromised the results.

Q: Where has the lawsuit been filed?
A: The case has been lodged in the U.S. District Court for the Southern District of New York under the Private Securities Litigation Reform Act of 1995.

Q: What actions can shareholders take now?
A: Interested shareholders should submit their details for a no-cost evaluation of their potential recoveries. Participation does not require immediate action but assures eligibility as an absent class member.

Q: If I sold my shares, can I still participate?
A: Yes! Eligibility pertains to the purchase period, meaning prior sellers can still seek compensation if they bought shares during the class period and suffered losses.

Conclusion

The upcoming October deadline for lead plaintiffs presents a critical opportunity for affected investors to assert their rights in this significant class action. The situation surrounding Fractyl Health serves as a stark reminder of the volatility in the biopharmaceutical sector and the importance of understanding financial disclosures when investing.

For further inquiries or to evaluate potential participation, contact Joseph E. Levi at Levi & Korsinsky, LLP.